(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of 23.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Voyager Therapeutics's revenue in 2026 is $40,374,000.On average, 14 Wall Street analysts forecast VYGR's revenue for 2026 to be $3,205,015,990, with the lowest VYGR revenue forecast at $233,629,550, and the highest VYGR revenue forecast at $7,734,210,894. On average, 13 Wall Street analysts forecast VYGR's revenue for 2027 to be $3,675,493,456, with the lowest VYGR revenue forecast at $1,168,147,750, and the highest VYGR revenue forecast at $7,693,087,325.
In 2028, VYGR is forecast to generate $4,584,681,922 in revenue, with the lowest revenue forecast at $1,168,147,750 and the highest revenue forecast at $13,893,806,300.